Women at low risk for breast cancer recurrence can avoid chemotherapy: Initial trial findings support current practices

E-ISSN： 1097-0142|122|3|337-338

ISSN： 0008-543X

Source： Cancer, Vol.122, Iss.3, 2016-02, pp. : 337-338

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The STAR Trial: Evidence for Raloxifene as a Breast Cancer Risk Reduction Agent for Postmenopausal Women

By Bevers Therese B.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 8, 2007-09 ,pp. : 817-822

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Tamoxifen a worthwhile investment for women at risk for breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Tamoxifen a worthwhile investment for women at risk for breast cancer

Inpharma, Vol. 1, Iss. 1227, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer

Current Pharmaceutical Design, Vol. 6, Iss. 3, 2000-02 ,pp. : 327-343

Bentham Science Publishers

Access to resources Recommend Favorite

Chemotherapy for all younger women with breast cancer?

Inpharma, Vol. 1, Iss. 1226, 2000-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite